Antibody Drug Conjugates Contract Market by Condition (Breast Cancer, Myeloma, Lymphoma), by Linker (Non-cleavable Linker, Cleavable Linker), and by Region - Global Forecast to 2023-2033

The antibody drug conjugates contract market size is estimated to be USD 9,867.1 million in 2022 and is expected to witness a CAGR of 12.99% during the forecast period 2023-2033. The complexity of ADCs and rising demand for manufacturing capacity are projected to drive the market growth in near future. Furthermore, increase in research on antibody therapeutics and surge in collaborations to increase the demand for ADC CMO activities are other factors supporting the market growth. However, high price of medicine development and distribution and a shortage of skilled workers are predicted to limit market growth.

Increase in research on antibody therapeutics is expected to spur the market growth during the projected period. Scientists have improved the design and development process for these medications over time and through research. Four new ADCs will therefore be approved between 2019 and 2020. There are now 100 ADCs awaiting approval by the US Food and Drug Administration.

Surge in collaborations to increase the demand for ADC CMO activities is predicted to fuel the market growth during the forecast period. In order to give their customers high-quality ADCs, ADC CMOs also invest to enhance their bioconjugation and manufacturing capabilities. For instance, the biotechnology company Singzyme and CMO Lonza partnered in October 2022. According to the collaboration, Lonza may produce ADC more rapidly by using Singzyme’s enzymatic conjugation platform. These partnerships would increase the demand for ADC CMO activities and thus help the sector expand. Over 14 ADCs had received worldwide commercial approval as of 2021, according to the European Pharmaceutical Review (EPR). Over 140 ADCs are currently being developed, according to the EPR.

Segmentation

 

By Condition

The market is categorized into breast cancer, myeloma, lymphoma and others (urothelial cancer). In 2022, the myeloma segment accounted for the highest revenue share due to the fact that they have a great potential for usage in the treatment of myeloma. A new type of medication called ADCs for myeloma targets only the myeloma cell with a potent cytotoxic chemical. Bystander cell damage is decreased and a therapeutic window is made accessible by this method of action. It can be used for a wide range of patients and in practically all myeloma treatment clinics. These factors are boosting ADC’s demand for myeloma therapy and driving the segment’s expansion. The lymphoma segment is anticipated to have the fastest CAGR over the forecast period. Many people around the world are affected by lymphoma. According to Cancer Tomorrow, there will be 83,100 new cases of Hodgkin lymphoma worldwide in 2020, compared to more than 544,000 new cases of non-Hodgkin lymphoma. There are three ADC treatments for lymphoma that are currently approved: Adcetris, Polivy, and Zynlonta. The majority of the commercially available ADCs are employed in the management of lymphoma and breast cancer.

By Linker

The market is segmented into non-cleavable linker and cleavable linker. In the global market, the cleavable linker segment accounted for the largest revenue share in 2022 owing to advantages that cleavable linkers provide in some situations to deliver the medication to the target cell. The success of an ADC is believed to be largely dependent on the properties of the linker that connects the antibody and the payload. The efficiency of cleavable linkers is due to their ability to effectively differentiate between circulatory and target-cell conditions. The non-cleavable linker segment is anticipated to register the fastest CAGR over the projected period. ADCs made with a non-cleavable linker depend on the lysosomal breakdown of the ADC, which releases the cytotoxic chemicals once the ADC molecule has been internalized in the target cell. The total cytotoxicity of the ADC to neighbouring healthy cells is decreased as a result of limiting the drug’s non-specific release. Non-cleavable linkers also have a longer half-life in circulation and higher plasma stability than cleavable linkers, both of which can increase the therapeutic window. The segment growth is being aided by the factors listed above.

Regional Markets

 

In 2022, Asia Pacific region accounted for the highest revenue in the antibody drug conjugates contract market and is expected to maintain its dominance during the forecast period. This is attributed to prevalence of cancer. 9.4 million cases of cancer were reported in Asia in 2020, and Cancer Tomorrow predicts that this figure would increase to 14.2 million by 2040. Thus, an increase in cancer cases is anticipated to enhance the market for ADC’s manufacturing by increasing the demand for targeted medicines like it. In addition, compared to industrialized economies, contract manufacturing costs are relatively low in the Asia-Pacific region. Additionally, North America contributed significantly to sales in 2022. This expansion can be attributed to the increase in biopharmaceutical companies in the United States and Canada. The expansion of important players in this region is anticipated to have a impact on the growth of the area. Additionally, the regional regulatory authority actively grants ADCs regulatory approval. For instance, as of 2021, the USFDA had approved 12 ADCs. This increases its commercial viability and encourages the region’s acceptance of it.

Competitor Insights

Some of the key players operating in the antibody drug conjugates contract market are Sartorius AG, Lonza, Samsung BioLogics, Recipharm AB, Piramal Group (Piramal Pharma Solutions), Abbvie, Inc. (Abbvie Contract Manufacturing), Catalent, Inc., Wuxi Biologics, Sterling, and Merck KGaA.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

  • For instance, Sterling invested USD 1.3 million in April 2022 to expand its U.K. site, which is focused to enhancing cGMP bioconjugation/ADC production capabilities.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including condition and linker from 2022 to 2033.

Report Scope:

Key Parameters Details
Market size in 2022
  • USD 9,867.1 Million
CAGR
  • 12.99%
Base Year
  • 2022
Forecast Period
  • 2023-2033
Study Coverage
  • Global and regional market size and revenue forecast
  • Segment market size and revenue forecast at global, regional, and country level
  • Competitive landscape (company share analysis, company profiles, recent development, competitive map analysis)
  • Conclusion and recommendations
Qualitative Analysis
  • Market drivers
  • Market restraints
  • Market opportunities
  • Recent market trends
  • Market challenges
  • Porter’s Five Forces analysis
  • PEST analysis
  • COVID-19 impact analysis
Segment Market Scope
  • Condition
  • Linker
Regional Market Scope
  • North America
    (U.S. and Canada)
  • Europe
    (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific
    (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America
    (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA
    (South Africa, GCC, Rest of MEA)
Company Profiles
  • Exhaustive profiles of top 10 players
  • Other major players listing
15% Free Customization Available
  • You can customize the study scope to meet your exact requirement. Click here for more details

Segmentation: Antibody Drug Conjugates Contract Market Report 2022 – 2033

Condition (Revenue, USD Million), 2022 – 2033

  • Breast Cancer
  • Myeloma
  • Lymphoma
  • Others (Urothelial Cancer)

Linker (Revenue, USD Million), 2022 – 2033

  • Non-cleavable Linker
  • Cleavable Linker

By Region (Revenue, USD Million), 2022 – 2033

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Table of Contents: Antibody Drug Conjugates Contract Market 2022-2033

  1. Research Methodology
    1. Study Objectives
    2. Study Scope
    3. Research Framework
      1. Research Models
        1. Bottom-up Approach
        2. Top-down Approach
        3. Data Triangulation
      2. Data Analysis
        1. Data Validation
        2. Market Size Estimation
        3. Market Forecast Model
  1. Introduction: Antibody Drug Conjugates Contract
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
      1. Driver 1
      2. Driver 2
      3. Driver 3
      4. Driver 4
      5. Driver 5
    2. Market Restraint
      1. Restraint 1
      2. Restraint 2
      3. Restraint 3
      4. Restraint 4
    3. Market Opportunities
      1. Opportunity 1
      2. Opportunity 2
      3. Opportunity 3
      4. Opportunity 4
    4. Market Trends
      1. Trend 1
      2. Trend 2
      3. Trend 3
      4. Trend 4
    5. Market Challenges
      1. Challenge 1
      2. Challenge 2
      3. Challenge 3
      4. Challenge 4
  1. Market Environment Analysis
    1. Porter’s 5 Forces Analysis
    2. PESTEL Analysis
    3. SWOT Analysis
  2. COVID-19 Impact Analysis: Antibody Drug Conjugates Contract Market  
  3. Market Analysis by Condition
    1. Breast Cancer
      1. Breast Cancer Market Forecast, 2022-2033(USD Million)
    2. Myeloma
      1. Myeloma Market Forecast, 2022-2033(USD Million)
    3. Lymphoma
      1. Lymphoma Market Forecast, 2022-2033(USD Million)
    4. Others (Urothelial Cancer)
      1. Others (Urothelial Cancer) Market Forecast, 2022-2033(USD Million)
  1. Market Analysis byLinker
    1. Non-cleavable Linker
      1. Non-cleavable Linker Market Forecast, 2022-2033(USD Million)
    2. Cleavable Linker
      1. Cleavable Linker Market Forecast, 2022-2033(USD Million)
  1. Regional Market Analysis
    1. Regional Market Trends
  2. North America Antibody Drug Conjugates Contract Market  
    1. North America Antibody Drug Conjugates Contract Market
      1. North America Market Size and Forecast, 2022-2033(USD Million)
        1. Market Size and Forecast by Condition, 2022-2033(USD Million)
        2. Market Size and Forecast by Linker, 2022-2033(USD Million)
      2. S. Antibody Drug Conjugates Contract Market
        1. S. Market Size and Forecast, 2022-2033(USD Million)
          1. Market Size and Forecast by Condition, 2022-2033(USD Million)
          2. Market Size and Forecast by Linker, 2022-2033(USD Million)
        2. Canada Antibody Drug Conjugates Contract Market
          1. Canada Market Size and Forecast, 2022-2033(USD Million)
            1. Market Size and Forecast by Condition, 2022-2033(USD Million)
            2. Market Size and Forecast by Linker, 2022-2033(USD Million)
  1. Europe Antibody Drug Conjugates Contract Market  
    1. Europe Antibody Drug Conjugates Contract Market
      1. Europe Market Size and Forecast, 2022-2033(USD Million)
        1. Market Size and Forecast by Condition, 2022-2033(USD Million)
        2. Market Size and Forecast by Linker, 2022-2033(USD Million)
      2. Germany Antibody Drug Conjugates Contract Market
        1. Germany Market Size and Forecast, 2022-2033(USD Million)
          1. Market Size and Forecast by Condition, 2022-2033(USD Million)
          2. Market Size and Forecast by Linker, 2022-2033(USD Million)
        2. UK Antibody Drug Conjugates Contract Market
          1. UK Market Size and Forecast, 2022-2033(USD Million)
            1. Market Size and Forecast by Condition, 2022-2033(USD Million)
            2. Market Size and Forecast by Linker, 2022-2033(USD Million)
          2. France Antibody Drug Conjugates Contract Market
            1. France Market Size and Forecast, 2022-2033(USD Million)
              1. Market Size and Forecast by Condition, 2022-2033(USD Million)
              2. Market Size and Forecast by Linker, 2022-2033(USD Million)
            2. Spain Antibody Drug Conjugates Contract Market
              1. Spain Market Size and Forecast, 2022-2033(USD Million)
                1. Market Size and Forecast by Condition, 2022-2033(USD Million)
                2. Market Size and Forecast by Linker, 2022-2033(USD Million)
              2. Italy Antibody Drug Conjugates Contract Market
                1. Italy Market Size and Forecast, 2022-2033(USD Million)
                  1. Market Size and Forecast by Condition, 2022-2033(USD Million)
                  2. Market Size and Forecast by Linker, 2022-2033(USD Million)
                2. Rest of Europe Antibody Drug Conjugates Contract Market
                  1. Rest of Europe Market Size and Forecast, 2022-2033(USD Million)
                    1. Market Size and Forecast by Condition, 2022-2033(USD Million)
                    2. Market Size and Forecast by Linker, 2022-2033(USD Million)
  1. Asia Pacific Antibody Drug Conjugates Contract Market  
    1. Asia Pacific Antibody Drug Conjugates Contract Market
      1. Asia Pacific Market Size and Forecast, 2022-2033(USD Million)
        1. Market Size and Forecast by Condition, 2022-2033(USD Million)
        2. Market Size and Forecast by Linker, 2022-2033(USD Million)
      2. Japan Antibody Drug Conjugates Contract Market
        1. Japan Market Size and Forecast, 2022-2033(USD Million)
          1. Market Size and Forecast by Condition, 2022-2033(USD Million)
          2. Market Size and Forecast by Linker, 2022-2033(USD Million)
        2. China Antibody Drug Conjugates Contract Market
          1. China Market Size and Forecast, 2022-2033(USD Million)
            1. Market Size and Forecast by Condition, 2022-2033(USD Million)
            2. Market Size and Forecast by Linker, 2022-2033(USD Million)
          2. India Antibody Drug Conjugates Contract Market
            1. India Market Size and Forecast, 2022-2033(USD Million)
              1. Market Size and Forecast by Condition, 2022-2033(USD Million)
              2. Market Size and Forecast by Linker, 2022-2033(USD Million)
            2. South Korea Antibody Drug Conjugates Contract Market
              1. South Korea Market Size and Forecast, 2022-2033(USD Million)
                1. Market Size and Forecast by Condition, 2022-2033(USD Million)
                2. Market Size and Forecast by Linker, 2022-2033(USD Million)
                3. Market Size and Forecast by Device, 2022-2033(USD Million)
              2. Australia Antibody Drug Conjugates Contract Market
                1. Australia Market Size and Forecast, 2022-2033(USD Million)
                  1. Market Size and Forecast by Condition, 2022-2033(USD Million)
                  2. Market Size and Forecast by Linker, 2022-2033(USD Million)
                2. Rest of Asia Pacific Antibody Drug Conjugates Contract Market
                  1. Rest of Asia Pacific Market Size and Forecast, 2022-2033(USD Million)
                    1. Market Size and Forecast by Condition, 2022-2033(USD Million)
                    2. Market Size and Forecast by Linker, 2022-2033(USD Million)
  1. Latin America Antibody Drug Conjugates Contract Market  
    1. Latin America Antibody Drug Conjugates Contract Market
      1. Latin America Market Size and Forecast, 2022-2033(USD Million)
        1. Market Size and Forecast by Condition, 2022-2033(USD Million)
        2. Market Size and Forecast by Linker, 2022-2033(USD Million)
      2. Brazil Antibody Drug Conjugates Contract Market
        1. Brazil Market Size and Forecast, 2022-2033(USD Million)
          1. Market Size and Forecast by Condition, 2022-2033(USD Million)
          2. Market Size and Forecast by Linker, 2022-2033(USD Million)
        2. Mexico Antibody Drug Conjugates Contract Market
          1. Mexico Market Size and Forecast, 2022-2033(USD Million)
            1. Market Size and Forecast by Condition, 2022-2033(USD Million)
            2. Market Size and Forecast by Linker, 2022-2033(USD Million)
          2. Argentina Antibody Drug Conjugates Contract Market
            1. Argentina Market Size and Forecast, 2022-2033(USD Million)
              1. Market Size and Forecast by Condition, 2022-2033(USD Million)
              2. Market Size and Forecast by Linker, 2022-2033(USD Million)
            2. Rest of Latin America Antibody Drug Conjugates Contract Market
              1. Rest of Latin America Market Size and Forecast, 2022-2033(USD Million)
                1. Market Size and Forecast by Condition, 2022-2033(USD Million)
                2. Market Size and Forecast by Linker, 2022-2033(USD Million)
  1. MEA Antibody Drug Conjugates Contract Market  
    1. MEA Antibody Drug Conjugates Contract Market
      1. MEA Market Size and Forecast, 2022-2033(USD Million)
        1. Market Size and Forecast by Condition, 2022-2033(USD Million)
        2. Market Size and Forecast by Linker, 2022-2033(USD Million)
      2. GCC Antibody Drug Conjugates Contract Market
        1. GCC Market Size and Forecast, 2022-2033(USD Million)
          1. Market Size and Forecast by Condition, 2022-2033(USD Million)
          2. Market Size and Forecast by Linker, 2022-2033(USD Million)
        2. South Africa Antibody Drug Conjugates Contract Market
          1. South Africa Market Size and Forecast, 2022-2033(USD Million)
            1. Market Size and Forecast by Condition, 2022-2033(USD Million)
            2. Market Size and Forecast by Linker, 2022-2033(USD Million)
          2. Rest of MEA Antibody Drug Conjugates Contract Market
            1. Rest of MEA Market Size and Forecast, 2022-2033(USD Million)
              1. Market Size and Forecast by Condition, 2022-2033(USD Million)
              2. Market Size and Forecast by Linker, 2022-2033(USD Million)
  1. Competitor Analysis
    1. Market Share Analysis, 2022
    2. Major Recent Developments, 2019-2022
  2. Company Profiles
    1. Sartorius AG
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    2. Lonza
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    3. Samsung BioLogics
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    4. Recipharm AB
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    5. Piramal Group (Piramal Pharma Solutions)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    6. Abbvie, Inc. (Abbvie Contract Manufacturing)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    7. Catalent, Inc.
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    8. Wuxi Biologics
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    9. Sterling
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    10. Merck KGaA
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    11. Company 11
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    12. Company 12
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    13. Company 13
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    14. Company 14
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    15. Company 15
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Condition Benchmarking
      5. Recent Developments
    16. Others Prominent Players
  3. Conclusion & Recommendations

Leave a comment

Your email address will not be published. Required fields are marked *

Select License Type

5 reasons to choose Quintana Research Reports

Our top-quality, real-time, accurate, and data-driven research aims at empowering the clients with actionable insights.

We deliver timely data-driven insights to help clients make informed decisions and achieve growth and success.

Our team of experts is available 24*7 to offer incisive analysis of the market for clients.

We offer comprehensive and bespoke marketing research as per clients’ requirements.

Our cost-effective and rapid research helps clients gain competitive intelligence, and uncover potential opportunities & threats.